Charles River Laboratories International, Inc. · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$226.77 RISE2026-05-18$149.93 PEAK2026-05-28$181.34 127d | -33.9% 117d | Missed | Missed | — | — | +20.9% 10d | Missed |
DROP2026-01-21$226.77 RISE2026-03-16$151.97 PEAK2026-04-20$185.54 89d | -33.0% 54d | Missed | Missed | — | — | +22.1% 35d | Missed |
DROP2025-10-24$197.04 RISE2025-11-19$161.64 PEAK2026-01-21$226.77 89d | -18.0% 26d | Missed | Missed | — | — | +40.3% 63d | Missed |
DROP2025-07-28$178.99 RISE2025-09-25$145.57 PEAK2025-12-15$198.15 140d | -18.7% 59d | Missed | Missed | — | — | +36.1% 81d | Missed |
DROP2025-07-28$178.99 RISE2025-08-08$148.74 PEAK2025-10-24$197.04 88d | -16.9% 11d | Missed | Missed | — | — | +32.5% 77d | Missed |
DROP2024-12-09$201.75 RISE2025-04-11$99.75 PEAK2025-07-10$163.66 213d | -50.6% 123d | Missed | Missed | — | — | +64.1% 90d | Missed |
DROP2024-11-11$220.69 RISE2025-02-14$151.99 PEAK2025-03-18$176.94 127d | -31.1% 95d | Missed | Missed | — | — | +16.4% 32d | Missed |
DROP2024-07-30$245.29 RISE2024-10-31$178.58 PEAK2024-11-11$220.69 104d | -27.2% 93d | Missed | Missed | — | — | +23.6% 11d | Missed |
DROP2024-07-30$245.29 RISE2024-09-06$187.96 PEAK2024-11-11$220.69 104d | -23.4% 38d | Missed | Missed | — | — | +17.4% 66d | Missed |
DROP2024-03-21$273.43 RISE2024-07-05$199.66 PEAK2024-07-30$245.29 131d | -27.0% 106d | Missed | Missed | — | — | +22.9% 25d | Missed |
DROP2023-08-10$217.61 RISE2023-10-30$164.52 PEAK2023-12-27$238.84 139d | -24.4% 81d | Missed | Missed | — | — | +45.2% 58d | Missed |
DROP2022-11-15$250.07 RISE2022-12-12$201.94 PEAK2023-02-02$259.92 79d | -19.2% 27d | Missed | Missed | — | — | +28.7% 52d | Missed |
DROP2022-07-29$250.54 RISE2022-09-27$182.44 PEAK2022-11-15$250.07 109d | -27.2% 60d | Missed | Missed | — | — | +37.1% 49d | Missed |
DROP2022-02-09$346.96 RISE2022-06-17$204.13 PEAK2022-07-29$250.54 170d | -41.2% 128d | Missed | Missed | — | — | +22.7% 42d | Missed |
DROP2021-11-02$431.95 RISE2022-03-14$255.51 PEAK2022-04-08$302.40 157d | -40.8% 132d | Missed | Missed | — | — | +18.4% 25d | Missed |
1–15 / 16 1 / 2 | |||||||
Best Buy downgrade, Dell upgraded: Wall Street's top analyst calls
Pre-Market Stock Futures: Futures are trading higher after yet another winning day for Wall Street, as all major indices finished the day higher after starting the session lower. Once again, all four indices we track for readers posted all-time highs as the AI/Data Center, Memory Chip rally continues to roll on. Healthcare and consumer stocks ... Here Are Friday’s Top Wall Street Analyst Research Calls: Best Buy, Cogent Communications, Dell Technologies, EPAM Systems, Federal Realty, Gap, Snowfl
Charles River Laboratories has underperformed the S&P 500 over the past 52 weeks, yet Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Ariel Investmentsâ Q1 2026 13F: portfolio fell to $8.93B; biggest adds/trims and top holdings.
Earlier in May 2026, Charles River Laboratories and MEDIPOST signed a non-exclusive MOU to collaborate on GMP-compliant testing and commercialization support for cell therapies across APAC and North America, while the company also highlighted major AI-enabled enhancements to its end-to-end digital pathology platform. Together, these moves strengthen Charles River’s role in advanced biologics and cell therapies while using AI-driven workflows to speed studies and support reduced animal use...
Earlier in May 2026, Charles River Laboratories and MEDIPOST signed a non-exclusive MOU to collaborate on GMP-compliant testing and commercialization support for cell therapies across APAC and North America, while the company also highlighted major AI-enabled enhancements to its end-to-end digital pathology platform. Together, these moves strengthen Charles River’s role in advanced biologics and cell therapies while using AI-driven workflows to speed studies and support reduced animal use...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the impact of strategic divestitures, portfolio optimization, and cost-saving measures as key factors shaping performance. CEO Birgit Girshick highlighted that “incremental efficiency initiatives and divestitures” were central to margin improvement efforts, while the company also navigated discrete margin headwinds, including higher costs in its
Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the impact of strategic divestitures, portfolio optimization, and cost-saving measures as key factors shaping performance. CEO Birgit Girshick highlighted that “incremental efficiency initiatives and divestitures” were central to margin improvement efforts, while the company also navigated discrete margin headwinds, including higher costs in its
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.
U.S. stocks ended the week mostly unchanged amid persistent inflation pressures and surging Treasury yields. Read more about this week's major events on Wall Street.
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Transgenic Animals Market size & share revenue was valued at approximately USD 3.42 Billion in 2025 and is expected to reach USD 3.76 Billion in 2026 and is expected to reach around USD 7.89 Billion by 2035, at a CAGR of 10.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are The Jackson Laboratory, Charle
WILMINGTON, Mass., May 13, 2026--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River’s expertise in biologics and cell therapy GMP testing to support MEDIPOST’s global cell therapy pipeline, starting in th
Partnership showcases a forward-looking collaboration model that highlights advanced testing expertiseCharles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on year to $995.8 million. Its non-GAAP profit of $2.06 per share was 6% above analysts’ consensus estimates.
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on year to $995.8 million. Its non-GAAP profit of $2.06 per share was 6% above analysts’ consensus estimates.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CRL | +9.01% | +1.18% | -9.41% | +33.24% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.04% | +6.89% | -5.97% | +20.55% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | F Tax withholding | 105 | $156.73 | −$16.5K |
| 2026-05-28 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | F Tax withholding | 168 | $160.30 | −$26.9K |
| 2026-05-28 | Parisotto Shannon M | CEVP, Disc & Safety Assessment | G Gift | 7,169 | — | +$0 |
| 2026-05-28 | LaPlume Joseph W | EVP, Corp Strategy & Develop | F Tax withholding | 185 | $156.73 | −$29.0K |
| 2026-05-28 | LaPlume Joseph W | EVP, Corp Strategy & Develop | F Tax withholding | 243 | $160.30 | −$39.0K |
| 2026-05-28 | Knell Michael Gunnar | SVP, Finance and CAO | F Tax withholding | 37 | $156.73 | −$5.8K |
| 2026-05-28 | Knell Michael Gunnar | SVP, Finance and CAO | F Tax withholding | 50 | $160.30 | −$8.0K |
| 2026-05-28 | Girshick Birgit | Chief Executive Officer | F Tax withholding | 242 | $156.73 | −$37.9K |
| 2026-05-28 | Girshick Birgit | Chief Executive Officer | F Tax withholding | 376 | $160.30 | −$60.3K |
| 2026-05-28 | Mintz Mark | EVP, Chief Information Officer | F Tax withholding | 47 | $156.73 | −$7.4K |
| 2026-05-28 | Mintz Mark | EVP, Chief Information Officer | F Tax withholding | 64 | $160.30 | −$10.3K |
| 2026-05-28 | Creamer Victoria L | EVP & Chief People Officer | F Tax withholding | 148 | $156.73 | −$23.2K |
| 2026-05-28 | Creamer Victoria L | EVP & Chief People Officer | F Tax withholding | 198 | $160.30 | −$31.7K |
| 2026-05-12 | Graves Paul W | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-12 | Thompson Craig B. | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-12 | Barg Steven | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | FOSTER JAMES C | Director | A Grant / award | 422 | $177.62 | +$75.0K |
| 2026-05-11 | FOSTER JAMES C | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | WILSON VIRGINIA M | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | Kemps-Polanco Reshema | Director | A Grant / award | 535 | $177.62 | +$95.0K |
| 2026-05-11 | Kemps-Polanco Reshema | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | Enyedy Mark J | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | Llado George Sr. | Director | A Grant / award | 450 | $177.62 | +$79.9K |
| 2026-05-11 | Llado George Sr. | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| 2026-05-11 | Andrews Nancy C | Director | A Grant / award | 1,438 | $177.62 | +$255.4K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 2.73 | — | — |
| 2026-05-07 | 0.91 | -0.30 | -133.15% |
| 2026-02-18 | 2.35 | 2.39 | +1.91% |
| 2025-11-05 | 2.34 | 2.43 | +3.86% |
| 2025-08-06 | 2.55 | 3.12 | +22.45% |
| 2025-05-07 | 2.07 | 2.34 | +12.78% |
| 2025-02-19 | 2.53 | 2.66 | +5.24% |
| 2024-11-06 | 2.42 | 2.59 | +6.88% |
| 2024-08-07 | 2.39 | 2.80 | +16.97% |
| 2024-05-09 | 2.06 | 2.27 | +9.98% |
| 2024-02-14 | 2.40 | 2.46 | +2.40% |
| 2023-11-08 | 2.37 | 2.72 | +14.86% |
| 2023-08-09 | 2.64 | 2.69 | +1.97% |
| 2023-05-11 | 2.59 | 2.78 | +7.43% |
| 2023-02-22 | 2.75 | 2.98 | +8.55% |
| 2022-11-02 | 2.50 | 2.63 | +5.40% |